March 29, 2001--CytoGenix Inc. (CYGX) announced today that its Form 10 has cleared comments with the Securities and Exchange Commission (SEC), and that as of today, the company became a reporting company upon the effectiveness of its registration statement on Form 10-SB filed with the United States Securities and Exchange Commission for the registration of its common stock under Section 12(g) of the Securities Exchange Act of 1934.
Chief Executive Officer of the company Malcolm Skolnick, PhD, JD, commented, ``This is an important step for the company and shareholders. With this milestone accomplished, the company can now concentrate on the closure of funding efforts and a return to the OTC Bulletin Board.'' The company's filings and financial reports are available on the SEC's EDGAR reporting site, www.freeedgar.com. Concurrent with clearing the SEC, the company has engaged Mann Frankfort Stein & Lipp, CPAs, LLP as its auditors.
Mann Frankfort Stein & Lipp, CPAs, LLP is a Houston accounting and professional services firm enjoying its 30th year and has grown to be the largest Houston-based accounting firm with a total staff of over 225 professionals. Mann Frankfort Stein & Lipp, CPAs, LLP provides both privately and publicly held firms and their shareholders with high quality financial and management consulting services that positively impact bottom line profitability and long term growth.
CytoGenix is a Houston-based biotechnology research and development company and a leader in the field of intracellular expression of single stranded DNA (ssDNA). Adequate expression of sequence specific ssDNA molecules within the cells is critical to the success of the genetic therapies involving triplex, antisense, aptamer and catalytic DNA applications.... |
